Last 46 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.85 | — | 8.46 | — | — | — | — | — | — | — | 837.68 | 170.14 | 117.00 |
| — | — | — | — | — | — | — | — | — | — | +701.6% | +260.1% | -34.1% | |
| P/S Ratio | 2.26 | 1.45 | 1.49 | 1.41 | 2.47 | 3.32 | 4.31 | 3.01 | 4.07 | 4.00 | 5.47 | 3.91 | 4.38 |
| — | -56.5% | -65.4% | -53.1% | -39.3% | -16.9% | -21.3% | -23.2% | -7.2% | +0.9% | +28.5% | -23.2% | -41.7% | |
| P/B Ratio | 0.97 | 0.62 | 0.59 | 0.61 | 0.82 | 1.15 | 1.19 | 0.91 | 1.18 | 1.17 | 1.59 | 1.21 | 1.22 |
| — | -46.4% | -50.6% | -32.2% | -30.7% | -1.3% | -25.2% | -25.0% | -3.4% | -0.6% | -37.5% | -62.4% | -72.2% | |
| P/FCF | — | 7.48 | — | 783.16 | — | 33.28 | — | 296.84 | — | — | — | 14.46 | — |
| — | -77.5% | — | +163.8% | — | — | — | +1953.2% | — | — | — | -84.1% | — | |
| EV / EBITDA | 20.79 | 20.68 | 36.36 | 22.95 | 17.81 | 20.30 | 29.31 | 19.30 | 26.92 | 21.62 | 29.89 | 21.79 | 26.91 |
| — | +1.8% | +24.1% | +18.9% | -33.8% | -6.1% | -1.9% | -11.4% | +0.0% | -63.1% | -34.3% | -25.9% | -64.2% | |
| EV / EBIT | 298.17 | — | 7.89 | — | 91.97 | — | 375.02 | 69.96 | 85.26 | 73.26 | 71.12 | 44.13 | 76.41 |
| — | — | -97.9% | — | +7.9% | — | +427.3% | +58.5% | +11.6% | — | -11.8% | +18.8% | -46.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Neogen Corporation's operating margin was -2.4% in Q2 2026, up 5.2 pp QoQ and down 9.8 pp YoY. Gross margin expanded 22.4% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.1% | 47.5% | 34.4% | 30.8% | 39.4% | 38.8% | 39.8% | 47.9% | 50.5% | 50.9% | 51.0% | 50.9% | 49.5% |
| — | +22.4% | -13.6% | -35.8% | -22.1% | -23.7% | -21.9% | -5.9% | +2.1% | +3.9% | +8.4% | +9.8% | +10.5% | |
| Operating Margin | 1.1% | -2.4% | -7.6% | -3.5% | 5.4% | 7.4% | 4.0% | 7.4% | 5.1% | 9.1% | 8.4% | 9.7% | 7.2% |
| — | -132.4% | -291.4% | -147.0% | +6.1% | -18.9% | -52.2% | -23.4% | -28.9% | +373.6% | +82.4% | -24.7% | +44.5% | |
| Net Margin | -122.1% | -7.1% | 17.4% | -271.5% | -5.0% | -197.3% | -5.8% | -2.3% | -0.9% | -1.5% | 0.7% | 2.3% | 3.8% |
| — | +96.4% | +398.9% | -11773.9% | -461.1% | -12893.4% | -985.4% | -199.2% | -123.5% | +91.7% | -83.3% | -78.4% | -11.6% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.9% | -0.8% | 1.7% | -25.9% | -0.4% | -15.7% | -0.4% | -0.2% | -0.1% | -0.1% | 0.0% | 0.2% | 0.3% |
| — | +95.2% | +531.9% | -14927.2% | -539.5% | -14089.8% | -938.4% | -196.7% | -124.5% | +94.7% | -91.9% | -89.5% | -58.0% | |
| ROA | -27.3% | -0.5% | 1.1% | -16.4% | -0.3% | -10.7% | -0.3% | -0.1% | -0.0% | -0.1% | 0.0% | 0.1% | 0.2% |
| — | +95.6% | +483.9% | -13759.9% | -515.7% | -13913.4% | -940.9% | -196.0% | -124.4% | +95.0% | -93.8% | -91.9% | -67.7% | |
| ROIC | 0.2% | -0.1% | -0.4% | -0.2% | 0.3% | 0.3% | 0.2% | 0.3% | 0.2% | 0.4% | 0.4% | 0.4% | 0.3% |
| — | -141.8% | -355.2% | -155.3% | +15.3% | -14.3% | -55.1% | -24.4% | -23.8% | +267.2% | -33.7% | -72.1% | -48.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Neogen Corporation's Debt/EBITDA ratio is 33.7x, down from 60.6x last quarter — elevated, raising questions about debt serviceability.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.44 | 0.38 | 0.37 | 0.44 | 0.34 | 0.33 | 0.28 | 0.29 | 0.28 | 0.28 | 0.28 | 0.29 | 0.28 |
| — | +12.7% | +31.5% | +52.9% | +18.7% | +18.3% | +0.7% | +0.7% | -0.0% | -5.0% | — | +17522.4% | — | |
| Debt / EBITDA | 6.76 | 33.67 | 60.62 | 40.76 | 21.59 | 18.94 | 23.19 | 19.52 | 21.53 | 17.66 | 18.57 | 17.31 | 20.50 |
| — | +77.8% | +161.4% | +108.8% | +0.3% | +7.3% | +24.9% | +12.8% | +5.0% | -63.5% | — | +28572.2% | — | |
| Current Ratio | 3.32 | 3.91 | 3.58 | 3.32 | 3.91 | 3.77 | 4.41 | 3.82 | 3.82 | 3.54 | 4.23 | 4.03 | 5.18 |
| — | +3.6% | -18.7% | -13.2% | +2.4% | +6.7% | +4.3% | -5.2% | -26.4% | -16.2% | -53.4% | -50.0% | -44.0% | |
| Quick Ratio | 2.22 | 2.80 | 2.26 | 2.22 | 2.45 | 2.46 | 2.79 | 2.59 | 2.66 | 2.63 | 3.21 | 3.11 | 3.84 |
| — | +13.8% | -18.9% | -14.4% | -7.9% | -6.3% | -13.1% | -16.6% | -30.7% | -21.0% | -55.1% | -52.0% | -49.0% | |
| Interest Coverage | 0.13 | -0.36 | -0.97 | -0.46 | 0.68 | 0.94 | 0.47 | 0.94 | 0.64 | 1.16 | 1.04 | 1.30 | 0.90 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NEOG stock.
Neogen Corporation's current P/E is -1.9x. The average P/E over the last 1 quarters is 8.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Neogen Corporation's current operating margin is 1.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Neogen Corporation's business trajectory between earnings reports.